Neuroscientific Biopharmaceuticals Ltd has released a press release.
Appendix 4C - quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Manufacturing Update
- Key Executive Appointments to Support Clinical Studies
- NSB to investigate treatment for post-COVID Fibrosis
- Strategic Placement to AlphaSwiss Partners
- Appendix 4E and Annual Report
Later from Neuroscientific Biopharmaceuticals
- Update on Pivotal Ocular Safety Studies
- R&D Tax Rebate Received
- NSB partners with Linear Research for Phase I Clinical Study
- Successful completion of pivotal ocular safety study
- Quarterly Update and Appendix 4C
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals